The Probiotics in Pediatric Asthma Management (PROPAM) Study in the Primary Care Setting: A Randomized, Controlled, Double-Blind Trial with Ligilactobacillus salivarius LS01 (DSM 22775) and Bifidobacterium breve B632 (DSM 24706)

Table 4

Maintenance therapy over time: intensity of asthma treatment in both groups.

	Placebo				Active treatment
	No therapy	Low intensity	Mild intensity	High intensity	No therapy	Low intensity	Mild intensity	High intensity
	83 (40.5%)	40 (19.5%)	38 (18.5%)	44 (21.5%)	95 (45.5%)	36 (17.2%)	30 (14.4%)	48 (23.0%)
	86 (42.2%)	41 (20.1%)	37 (18.1%)	40 (19.6%)	95 (46.6%)	33 (16.2%)	28 (13.7%)	48 (23.5%)
	99 (49.0%)	35 (17.3%)	29 (14.4%)	39 (19.3%)	98 (48.3%)	33 (16.3%)	31 (15.3%)	41 (20.2%)
	103 (51.5%)	33 (16.5%)	27 (13.5%)	37 (18.5%)	104 (51.7%)	38 (18.9%)	29 (14.4%)	30 (14.9%)
	123 (61.8%)	23 (11.6%)	25 (12.6%)	28 (14.1%)	115 (57.2%)	32 (15.9%)	24 (11.9%)	30 (14.9%)